Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL - DuRIANS (Durvalumab Revlimid In Aggressive NHL Subtypes)

Trial Profile

PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL - DuRIANS (Durvalumab Revlimid In Aggressive NHL Subtypes)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Lenalidomide (Primary)
  • Indications Diffuse large B cell lymphoma; Plasmablastic lymphoma
  • Focus Therapeutic Use
  • Acronyms DuRIANS
  • Most Recent Events

    • 11 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to FDA hold for combination studies using Imids and PD1/PDL1 compounds
    • 14 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top